Pharmasset, Inc. was founded in 1998 and is based in Princeton, New Jersey. Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing novel drugs to treat viral infections. Its primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection; and Racivir for the treatment of human immunodeficiency virus (HIV) infection. The company has three product candidates under development, which include RG7128, a HCV nucleoside polymerase inhibitor that is in Phase IIb clinical trial; PSI-7851, a HCV nucleotide polymerase inhibitor that completed Phase I clinical trial; and Racivir, which completed Phase II clinical trial, for the treatment of HIV. It has strategic collaboration agreement with F. Hoffmann-LaRoche Ltd. and Hoffmann-La Roche Inc. for the development of PSI-6130 and its products, including RG7128. The company also has collaboration and licensing agreements with University of Cincinnati; Apath, LLC; Emory University; Bukwang Pharm. Co., Ltd; University of Georgia Research Foundation, Inc. and Yale University; and Boehringer Ingelheim Chemicals, Inc.

A. Nelson & Co. is Europe's oldest and the UK's largest manufacturer of homeopathic medicines and other natural healthcare products. Its homeopathic creams, ointments, sprays, and tablets treat a range of health problems from common colds to skin conditions. Its formulated remedies include Travella for travel sickness, Teetha for teething discomfort, Coldenza for cold and flu symptoms, Noctura for insomnia, and Pollenna for hay fever. The company is the manufacturer of Bach floral remedies, including the popular Rescue Remedy. Nelson distributes its products worldwide and operates specialized manufacturing labs in the UK. The company is owned by the Wilson family.

XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of multiple myeloma (MM) and hepatitis C. The Company’s lead compound is Recombinant Erythropoietin (rHuEPO), a known compound that it is developing for the prolongation of MM patients' survival and improvement of their quality of life. MM is a severe and incurable malignant hematological cancer of plasma cells. XTL’s second program is the Diversity Oriented Synthesis program (DOS), which is focused on the development of pre-clinical hepatitis C small molecule inhibitors, which the Company had out-licensed to Presidio Pharmaceuticals, Inc. (Presidio), which is a private specialty pharmaceutical company on March 20, 2008.

ALK is a global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. We are devoted to improving quality of life for people with allergies by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction.

Charles River Laboratories International, Inc. company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions.

Elan Corporation, plc company was founded in 1969 and is headquartered in Dublin, Ireland. Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. Elan’s operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain. EDT focuses on the specialty pharmaceutical industry, including specialized drug delivery and manufacturing. In September 2009, the Company and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer`s Immunotherapy Program (AIP).

QLT Inc. company was founded in 1981 and is headquartered in Vancouver, Canada. QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, as well as OT-730, a prodrug of a beta adrenergic antagonist (a type of beta blocker) under investigation for the treatment of glaucoma.

Nile Therapeutics, Inc. company was founded in 2005 and is based in San Mateo, California. Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for the treatment of cardiovascular disease and other areas of unmet medical needs. The company focuses on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. Nile is also developing CU-NP, a novel, rationally designed natriuretic peptide.

Carma Laboratories, Inc. company was founded by Alfred Woelbing, who developed the formula for Carmex in 1937 as a treatment for his own cold sores. Carma Laboratories wants to make it easier for you to smile and sit. The family-owned-and-operated company is most famous for its retro yellow-lidded vials of Carmex lip balm. The company also makes Am-Ren, a zinc-oxide based diaper rash ointment, and LANEX hemorrhoid ointment to soothe cracked and painful tissues elsewhere. Once sold mostly in the Midwest and the ski areas of the Rockies, Carmex soothes lips in all 50 states, Canada, Australia, and Europe.

GW was founded in 1998. GW Pharmaceuticals has "high" hopes that its products will help relieve the pain and muscle stiffness that have resulted from cancer, multiple sclerosis, and surgery. The company develops prescription medicinal drugs derived from an hybrid form of cannabis that doesn't cause a psychotropic high. GW's lead drug candidate is Sativex, a whole-plant cannabis extract delivered by an oral spray. Sativex has been approved in Canada for the treatment of pain caused by multiple sclerosis. The company has agreed to let Bayer market the drug in the UK and Canada.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.